Dr. Griggs is an internist/neurologist specializing in neuromuscular diseases with a focus on experimental therapeutics. He has directed an NIH-funded training program in the Experimental Therapeutics of Neurological Disease since 1989. This program has trained over 50 clinical neuroscientists who are in positions around the world. He has published over 300 scientific papers and 19 texts which span the fields of medicine and neurology. He served as President of the Association of University Professor of Neurology (1994 Neurology ( -1996 . He has served on the Council of the American Neurological Association. He served as Editor-in-Chief of Neurology (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) Periodic paralyses (PPs) are rare inherited channelopathies that manifest as abnormal, often potassium (K)-sensitive, muscle membrane excitability leading to episodic flaccid paralysis. Hypokalaemic (HypoPP) and hyperkalaemic PP and Andersen-Tawil syndrome are genetically heterogeneous. Over the past decade mutations in genes encoding three ion channels, CACN1AS, SCN4A and KCNJ2, have been identified and account for at least 70% of the identified cases of PP and several allelic disorders. No prospective clinical studies have followed sufficiently large cohorts with characterized molecular lesions to draw precise conclusions. We summarize current knowledge of the clinical diagnosis, molecular genetics, genotype-phenotype correlations, pathophysiology and treatment in the PPs. We focus on unresolved issues including (i) Are there additional ion channel defects in cases without defined mutations? (ii) What is the mechanism for depolarization-induced weakness in Hypo PP? and finally (iii) Will detailed electrophysiological studies be able to correctly identify specific channel mutations? Understanding the pathophysiology of the potassium-sensitive PPs ought to reduce genetic complexity, allow subjects to be stratified during future clinical trials and increase the likelihood of observing true clinical effects. Ideally, therapy for the PPs will prevent attacks, avoid permanent weakness and improve quality of life. Moreover, understanding the skeletal muscle channelopathies will hopefully lead to insights into the more common central nervous system channel diseases such as migraine and epilepsy.
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